Li Yan, Yang Shoubo, Hao Chengcheng, Chen Janxin, Li Shan, Kang Zhuang, Kang Xun, Zhang Hongmei, Li Wenbin
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2020.191134.
To explore the effect of BRAF inhibitor on epithelioid glioblastoma (Ep-GBM) with BRAFV600E mutation.
A patient of Ep-GBM with BRAFV600E mutation underwent BRAF inhibition therapy. The rationale behind combined BRAF and MEK inhibition in Ep-GBM was reviewed.
Vemurafenib can initially inhibit the progression of Ep-GBM with BRAFV600E mutation. However, the tumor may become resistant to vemurafenib and then progress.
BRAF inhibition therapy can inhibit the progression of Ep-GBM with BRAFV600E mutation, but the subsequent resistance development leads to a poor outcome.
探讨BRAF抑制剂对具有BRAFV600E突变的上皮样胶质母细胞瘤（Ep-GBM）的作用。
一名具有BRAFV600E突变的Ep-GBM患者接受了BRAF抑制治疗。回顾了在Ep-GBM中联合BRAF和MEK抑制的理论依据。
维莫非尼最初可抑制具有BRAFV600E突变的Ep-GBM的进展。然而，肿瘤可能会对维莫非尼产生耐药性，随后进展。
BRAF抑制治疗可抑制具有BRAFV600E突变的Ep-GBM的进展，但随后出现的耐药性导致预后不良。
